Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/19
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy DeliveryGlobeNewsWire • 10/30/19
Clearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual MeetingGlobeNewsWire • 10/17/19
Clearside Biomedical Featured at Multiple European Scientific Retinal CongressesGlobeNewsWire • 09/19/19
Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With RegenxbioBenzinga • 09/04/19
Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare ConferenceGlobeNewsWire • 09/03/19
Clearside Stock Plummets After Company Hints At Complete Response Letter For Macular Edema DrugBenzinga • 08/22/19
Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)GlobeNewsWire • 08/22/19
Clearside Biomedical's (CLSD) CEO George Lasezkay on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/19
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19